PP 0121

Drug Profile

PP 0121

Alternative Names: PHAGOBURN E coli phage - Pherecydes; PP0121

Latest Information Update: 19 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pherecydes Pharma
  • Class Coliphages
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators; Cell membrane modulators; Cell wall modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Burn infections; Escherichia coli infections

Most Recent Events

  • 01 Jul 2015 Phase-I/II clinical trials in Burn infections in France (Topical) (NCT02116010)
  • 01 Jul 2015 Phase-I/II clinical trials in Escherichia coli infections in France (Topical) (NCT02116010)
  • 03 Jun 2014 Pherecydes Pharma plans a phase I/II trial for Burn infections caused by Escherichia coli in Belgium, France and Switzerland (Topical) (NCT02116010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top